SonoThera raised an oversubscribed $125 million Series B to push its ultrasound-mediated genetic medicine platform into clinical development. The funding supports lead programs in Duchenne muscular dystrophy and autosomal dominant polycystic kidney disease, according to the company. Backers included prominent pharma and venture investors, highlighting renewed interest in non-viral modalities that aim to reduce constraints seen with viral vectors and lipid nanoparticles. SonoThera’s approach uses microbubbles and targeted ultrasound to enhance delivery to tissues at the moment of dosing.